Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech). The authors also report a vaccine efficacy of 52.4% from after the first dose to before the second dose, but in their calculati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-04, Vol.384 (16), p.1576-1578
Hauptverfasser: Skowronski, Danuta M, De Serres, Gaston, Vergnes, Jean-Noel, Wang, Xiang, Absalon, Judith, Koury, Kenneth, Gruber, William C
Format: Artikel
Sprache:eng
Schlagworte:
BNT162 Vaccine
Coronaviruses
COVID-19
COVID-19 Vaccines
Humans
Life Sciences
mRNA
RNA, Messenger
SARS-CoV-2
Vaccine efficacy
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1578
container_issue 16
container_start_page 1576
container_title The New England journal of medicine
container_volume 384
creator Skowronski, Danuta M
De Serres, Gaston
Vergnes, Jean-Noel
Wang, Xiang
Absalon, Judith
Koury, Kenneth
Gruber, William C
description To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech). The authors also report a vaccine efficacy of 52.4% from after the first dose to before the second dose, but in their calculation, they included data that were collected during the first 2 weeks after the first dose, when immunity would have still been mounting. 1 We used documents submitted to the Food and Drug Administration 2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose . . .
doi_str_mv 10.1056/NEJMc2036242
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04526472v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2491071030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c735t-6cbef96fdcd3579a1c3aa2f00ea904bcb64ff580f29b653f90762ace7399ae923</originalsourceid><addsrcrecordid>eNqN0c9LwzAUB_AgipvTm2cp6EHB6svPNsc5plPmBJ1eQ5om2LG2s-kG--_t2BwiHvYugceHL-R9ETrFcIOBi9tR_-nZEKCCMLKH2phTGjIGYh-1AUgcskjSFjryfgLNYCYPUYtSLgVlcRvJN-1svQx0kQZ95zKjzTIoXVB_2uBuNMaCJCTIX0fdoFcusjTEMvjQxmSFPUYHTk-9Pdm8HfR-3x_3BuHw5eGx1x2GJqK8DoVJrJPCpSalPJIaG6o1cQBWS2CJSQRzjsfgiEwEp05CJIg2NqJSaisJ7aCrde6nnqpZleW6WqpSZ2rQHarVDhgngkVkgRt7ubazqvyaW1-rPPPGTqe6sOXcK8IkhojwmO9IsYzJrhQoNPT8D52U86po7qMIb44ZgWArdb1Wpiq9r6zb_guDWpWqfpfa8LNN6DzJbbrFPy024GIN8tyrwk7y_3O-AXm1oLs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2516270640</pqid></control><display><type>article</type><title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Skowronski, Danuta M ; De Serres, Gaston ; Vergnes, Jean-Noel ; Wang, Xiang ; Absalon, Judith ; Koury, Kenneth ; Gruber, William C</creator><creatorcontrib>Skowronski, Danuta M ; De Serres, Gaston ; Vergnes, Jean-Noel ; Wang, Xiang ; Absalon, Judith ; Koury, Kenneth ; Gruber, William C</creatorcontrib><description>To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech). The authors also report a vaccine efficacy of 52.4% from after the first dose to before the second dose, but in their calculation, they included data that were collected during the first 2 weeks after the first dose, when immunity would have still been mounting. 1 We used documents submitted to the Food and Drug Administration 2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc2036242</identifier><identifier>PMID: 33596348</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>BNT162 Vaccine ; Coronaviruses ; COVID-19 ; COVID-19 Vaccines ; Humans ; Life Sciences ; mRNA ; RNA, Messenger ; SARS-CoV-2 ; Vaccine efficacy ; Vaccines</subject><ispartof>The New England journal of medicine, 2021-04, Vol.384 (16), p.1576-1578</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c735t-6cbef96fdcd3579a1c3aa2f00ea904bcb64ff580f29b653f90762ace7399ae923</citedby><cites>FETCH-LOGICAL-c735t-6cbef96fdcd3579a1c3aa2f00ea904bcb64ff580f29b653f90762ace7399ae923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc2036242$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc2036242$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33596348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04526472$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Skowronski, Danuta M</creatorcontrib><creatorcontrib>De Serres, Gaston</creatorcontrib><creatorcontrib>Vergnes, Jean-Noel</creatorcontrib><creatorcontrib>Wang, Xiang</creatorcontrib><creatorcontrib>Absalon, Judith</creatorcontrib><creatorcontrib>Koury, Kenneth</creatorcontrib><creatorcontrib>Gruber, William C</creatorcontrib><title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech). The authors also report a vaccine efficacy of 52.4% from after the first dose to before the second dose, but in their calculation, they included data that were collected during the first 2 weeks after the first dose, when immunity would have still been mounting. 1 We used documents submitted to the Food and Drug Administration 2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose . . .</description><subject>BNT162 Vaccine</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>mRNA</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0c9LwzAUB_AgipvTm2cp6EHB6svPNsc5plPmBJ1eQ5om2LG2s-kG--_t2BwiHvYugceHL-R9ETrFcIOBi9tR_-nZEKCCMLKH2phTGjIGYh-1AUgcskjSFjryfgLNYCYPUYtSLgVlcRvJN-1svQx0kQZ95zKjzTIoXVB_2uBuNMaCJCTIX0fdoFcusjTEMvjQxmSFPUYHTk-9Pdm8HfR-3x_3BuHw5eGx1x2GJqK8DoVJrJPCpSalPJIaG6o1cQBWS2CJSQRzjsfgiEwEp05CJIg2NqJSaisJ7aCrde6nnqpZleW6WqpSZ2rQHarVDhgngkVkgRt7ubazqvyaW1-rPPPGTqe6sOXcK8IkhojwmO9IsYzJrhQoNPT8D52U86po7qMIb44ZgWArdb1Wpiq9r6zb_guDWpWqfpfa8LNN6DzJbbrFPy024GIN8tyrwk7y_3O-AXm1oLs</recordid><startdate>20210422</startdate><enddate>20210422</enddate><creator>Skowronski, Danuta M</creator><creator>De Serres, Gaston</creator><creator>Vergnes, Jean-Noel</creator><creator>Wang, Xiang</creator><creator>Absalon, Judith</creator><creator>Koury, Kenneth</creator><creator>Gruber, William C</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20210422</creationdate><title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</title><author>Skowronski, Danuta M ; De Serres, Gaston ; Vergnes, Jean-Noel ; Wang, Xiang ; Absalon, Judith ; Koury, Kenneth ; Gruber, William C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c735t-6cbef96fdcd3579a1c3aa2f00ea904bcb64ff580f29b653f90762ace7399ae923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>BNT162 Vaccine</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>mRNA</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skowronski, Danuta M</creatorcontrib><creatorcontrib>De Serres, Gaston</creatorcontrib><creatorcontrib>Vergnes, Jean-Noel</creatorcontrib><creatorcontrib>Wang, Xiang</creatorcontrib><creatorcontrib>Absalon, Judith</creatorcontrib><creatorcontrib>Koury, Kenneth</creatorcontrib><creatorcontrib>Gruber, William C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skowronski, Danuta M</au><au>De Serres, Gaston</au><au>Vergnes, Jean-Noel</au><au>Wang, Xiang</au><au>Absalon, Judith</au><au>Koury, Kenneth</au><au>Gruber, William C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-04-22</date><risdate>2021</risdate><volume>384</volume><issue>16</issue><spage>1576</spage><epage>1578</epage><pages>1576-1578</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech). The authors also report a vaccine efficacy of 52.4% from after the first dose to before the second dose, but in their calculation, they included data that were collected during the first 2 weeks after the first dose, when immunity would have still been mounting. 1 We used documents submitted to the Food and Drug Administration 2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>33596348</pmid><doi>10.1056/NEJMc2036242</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2021-04, Vol.384 (16), p.1576-1578
issn 0028-4793
1533-4406
language eng
recordid cdi_hal_primary_oai_HAL_hal_04526472v1
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine
subjects BNT162 Vaccine
Coronaviruses
COVID-19
COVID-19 Vaccines
Humans
Life Sciences
mRNA
RNA, Messenger
SARS-CoV-2
Vaccine efficacy
Vaccines
title Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20the%20BNT162b2%20mRNA%20Covid-19%20Vaccine&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Skowronski,%20Danuta%20M&rft.date=2021-04-22&rft.volume=384&rft.issue=16&rft.spage=1576&rft.epage=1578&rft.pages=1576-1578&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc2036242&rft_dat=%3Cproquest_hal_p%3E2491071030%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2516270640&rft_id=info:pmid/33596348&rfr_iscdi=true